DocDollars

Amicus Therapeutics, Inc.

NJ · United States · Reporting entity ID 100000381810

Total reported 2019–2025
$110.5M
#87 of 2,960 reporting companies — 0.1% of all reported industry payments
$2.30M in general payments across 1,813 records, plus $108.2M in research funding across 3,138 records.

How it breaks down

General payments $2,304,991
Research funding $108,183,413

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Amicus Therapeutics, Inc. reported $110.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #87 of 2,960 reporting companies. 98% of that was research funding and 2% general payments such as consulting, speaking, food and travel. 1,813 general payment records and 3,138 research records were filed.

Common questions about Amicus Therapeutics, Inc.

How much has Amicus Therapeutics, Inc. paid US doctors?

Amicus Therapeutics, Inc. reported $110,488,404 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,304,991 in general payments, $108,183,413 in research funding.

How does Amicus Therapeutics, Inc. rank among drug and device companies?

It ranks #87 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Amicus Therapeutics, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.